TCM Prescription: Ling Mao Xiang Jie Mei Pills



Prescription Description
Prescription IDTCMFx4251
Pinyin NameLing Mao Xiang Jie Mei Wan
Chinese Name灵猫香解霉丸
English NameLing Mao Xiang Jie Mei Pills
Function Description乳蛾, 烂喉丹痧, 疔疮, 痈疡, 乳痈, 无名肿痛
IndicationsTonsillitis disorder, Scarlet fever, Tonsillitis
Disease ICD-11 Category SC93 [Tonsillitis disorder (TM1), 乳蛾 (TM1) ];
1B50 [Scarlet fever, 猩红热 ];
CA0Z [Upper respiratory tract disorders, unspecified, 上呼吸道疾患,未特指的 ];
Human Tissues Associated with IndicationLung
ReferenceCFDA
Reference Book/linkhttp://samr.cfda.gov.cn/WS01/CL0001/
Prescription Components
Component ID Latin Name Chinese Name Component Quantity Barcode
TCMH1573 Bovis calculus 牛黄 TCMH1573
TCMH1291 Viverra zibetha 灵猫香 TCMH1291
TCMH233 Bufonis venenum 蟾酥 TCMH233
TCMH183 Dryobalanops aromatica 冰片 TCMH183 GBVK4926-11
TCMH2605 Margarita 珍珠 TCMH2605
TCMH2329 Realgar 雄黄 TCMH2329
Reference: CFDA

Targeted Human Proteins by the Ingredients of Prescription

Target ID Gene Symbol Target Name Target Class Uniprot ID
TCMT907 FDPS Farnesyl diphosphate synthase Lyase P14324


Targeted Pathogenic Microbes by the Ingredients of Prescription

Target ID Target Name
TCMT1229 Enterococcus faecalis
TCMT1255 Human immunodeficiency virus 1
TCMT1438 Plasmodium falciparum
TCMT1442 Leishmania donovani

Gene Ontology Associated to Targeted Human Proteins

GO Term GO Name Enriched Genes Log10 Adjusted P-value


KEGG Pathways Associated to Targeted Human Proteins

KEGG Pathway ID Enriched Genes Log10 Adjusted P-value


Target Exprsssion in Healthy Human Tissues (protein & mRNA level)

Protein expression data was from the "Human Proteome Map" dataset
mRNA expression data was from the "GTEx" dataset



Average Target Expression (Fold Change) in Multiple Disease Conditions

Fold Change with Corresponding Normal Samples
Click each cell within the heatmap to access gene expression of individual patient samples
Data Section
Select to Download
1. General Information of Prescription  
2. Putative Targets  
3. Activity & References for Filtering Putative Targets  
4. GO & Pathway